这项回顾性研究纳入2022年6月至2024年2月接受allo-HSCT的182例患者。2022年6月至2023年4月接受allo-HSCT的患者接受固定疗程(目标100天)来特莫韦治疗(固定疗程组,n=78),2023年2月至2024年2月接受allo-HSCT的患者根据CMV-CMI重建质量...
中的潜在价值。同时，明确ATLG在儿童移植预处理中的最佳适用场景，以推动个体化GVHD预防策略的优化升级。参考文献：1. Xiao Han, et al. 2025 EBMT. Abstract: P132.2. Li Nannan, et al. 2025 EBMT. Abstract: B114.审批号：P-20250328-012 本资料目的在于提供疾病领域的相关知识，提高疾病认知的水平 ...
1. Marie José Kersten, Kirsten Saevels, Sophie Servais, et al. SEVEN-DAY VEIN-TO-VEIN POINT-OF-CARE–MANUFACTURED CD19 CAR T-CELL THERAPY (GLPG5101) IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (NHL): RESULTS FRO...
第50届欧洲血液和骨髓移植学会(EBMT)年会近日于英国召开,会议中一篇研究“RRMM中靶向BCMA CAR-T药品的有效性匹配调整间接比较分析(MAIC)”[1]首次揭示了四款BCMA CAR-T药品的间接疗效比较,包括总缓解率(ORR)、完全缓解(CR)率以及微小残留病(MRD)阴性率,研究结果显示,在ORR方面,2023年在中国获批上市的全球首款...
EBMT 2023 - 49th Annual Meeting of the European Society for Blood and Marrow Transplantation Date: 23-26 April 2023 Venue: Paris, France 摘要征文投稿截止日期: 点此提交摘要>>>Submit Abstract>>> Notification letter sent to Nurses abstract authors on acceptance status:November 23, 2022 ...
Abstract submission deadline:December 17, 2023 Notification letter to abstract authors on acceptance status:February 13, 2024 Oral Schedule sent to abstract authors:February 13, 2024 Poster Schedule* sent to abstract authors:February 13, 2024
Abstract submission deadline:December 17, 2023 Notification letter to abstract authors on acceptance status:February 13, 2024 Oral Schedule sent to abstract authors:February 13, 2024 Poster Schedule* sent to abstract authors:February 13, 2024
Bone Marrow Transplantation volume 58, pages 1033–1041 (2023)Cite this article 1155 Accesses 4 Altmetric Metrics details Abstract Accessibility to allogeneic hematopoietic cell transplantation (HCT) programs for older patients is growing constantly. We report on the clinical outcomes of a group of 701...
2. F. Mehdid, M. Benakli, M. Baazizi, et al. ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PRIMARY MYELOFIBROSIS: ABOUT 6 CASES. The 48th Annual Meeting of the EBMT. Abstract P574.
Abstract Autologous hematopoietic stem cell transplantation (auto-HSCT) is the standard of care for patients with diffuse large B-cell lymphoma (DLBCL) who relapse/progress after first line chemoimmunotherapy. Long-term outcome of those who relapse after transplant is poor. We present the results ...